Skip to main content
Premium Trial:

Request an Annual Quote

BD Acquires GeneOhm Sciences for $230M in Bid to Bolster Infectious-Disease Play

NEW YORK, Jan. 10 (GenomeWeb News) - Becton Dickinson has acquired GeneOhm Sciences for $230 million plus up to $25 million in additional incentives, BD said today.


GeneOhm is a privately held company headquartered in San Diego that develops molecular diagnostics designed to detect bacteria known to cause healthcare-associated infections. BD said that GeneOhm had 2005 revenues of approximately $5 million, and provides BD with expanded entry into the emerging HAI market.


Specifically, GeneOhm markets FDA-cleared IDI-MRSA and IDI-Strep B diagnostic tests. MRSA, also known as methicillin-resistant Staphylococcus aureus, is responsible for HAIs, and Group B Strep poses a risk to pregnant women and their children during the latter stages of pregnancy.


The acquisition is subject to regulatory approvals and is expected to close by the end of March 2006. BD also said that the GeneOhm transaction is slightly dilutive. However, it reaffirms its previous guidance that reported diluted earnings per share from continuing operations for fiscal year 2006 are expected to be in the range of $3.15 to $3.19. BD said it will provide further details around this guidance during its first quarter earnings call on January 26.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.